Johnson & Johnson stock gains on raised 2026 guidance and strong Q2 growth

Published on 09/20/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock trades near USD 270 after the company raised its 2026 sales guidance to USD 101.1 billion on July 15, 2026 results. Analysts now see price targets up to USD 320 as the shares outpace the S&P 500 with a 57% one-year return.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) is trading around USD 270 as of September 19, 2026, supported by stronger guidance and robust second-quarter figures that lifted investor confidence in the healthcare group’s growth trajectory.

Guidance raised after July 15, 2026 results

According to Simplify, Johnson & Johnson released its latest quarterly results on July 15, 2026 and raised its full-year 2026 sales guidance to USD 101.1 billion.

In the same Q2 2026 update, the company reported that sales increased 6.6 percent year over year to USD 25.31 billion, underlining a solid expansion across key franchises in the middle of the year.

The group also projected adjusted earnings per share of USD 11.58 for fiscal 2026, while delivering adjusted EPS of USD 2.90 in Q2 2026, a figure that exceeded market expectations and signaled that profitability is tracking ahead of earlier assumptions.

Segment growth and pipeline support the stock

As Simplify reports, the immunology drug TREMFYA delivered 71 percent revenue growth in Q2 2026 and achieved its first USD 2 billion quarter, highlighting the strength of newer products in offsetting pressure in more mature brands.

The same analysis notes that biosimilar competition to STELARA reduced operational sales growth by 460 basis points in Q2 2026, but that excluding STELARA, Johnson & Johnson still achieved double-digit growth, an important risk factor and reassurance for investors watching the impact of patent expirations.

Johnson & Johnson stock has surged 57 percent over the past twelve months, compared with a 17 percent return for the S&P 500 over the same period, according to Simplify, indicating that investors are rewarding the company’s earnings momentum and product pipeline.

Analyst targets point to further upside

Analyst commentary has turned more constructive in recent days. In a report highlighted by The Globe and Mail on September 19, 2026, Scotiabank analyst Louise Chen maintained a Buy rating on Johnson & Johnson and set a price target of USD 305.

The same overview notes that UBS initiated coverage of Johnson & Johnson with a Buy rating and a price target of USD 320 in a report dated September 3, 2026, placing UBS’s target roughly USD 50 above the recent share price near USD 270.

According to the analyst consensus cited by The Globe and Mail, Johnson & Johnson is currently rated Strong Buy with an average price target of USD 286.61, implying about 6.9 percent upside from the level of roughly USD 270.

Valuation and earnings outlook

The valuation of Johnson & Johnson stock reflects both the strength of recent earnings and the transition away from STELARA. As Simplify points out, the shares trade at approximately 28.3 times trailing earnings at a price near USD 270, a multiple that looks high because the trailing figures still include the impact of STELARA’s declining contribution.

The same source indicates that the stock trades at 24.1 times projected fiscal 2026 earnings and 20.9 times 2027 estimates, suggesting a more moderate valuation if investors focus on forward earnings rather than backward-looking metrics that are distorted by product-specific headwinds.

Consensus estimates compiled by Zacks show that the 2026 earnings per share estimate for Johnson & Johnson has edged up from USD 11.59 to USD 11.61 over the past 30 days, while the 2027 EPS estimate has risen from USD 12.80 to USD 12.83 in the same period.

Dividend and income profile

For income-oriented investors, the dividend remains another important element of the Johnson & Johnson investment case. As 24/7 Wall St reported on September 20, 2026, Johnson & Johnson pays a quarterly dividend of USD 1.34 per share, corresponding to an annualized forward payout of USD 5.36 at a recent share price of USD 269.99.

This level of dividend support, combined with the raised sales guidance to USD 101.1 billion and the Q2 2026 revenue growth of 6.6 percent to USD 25.31 billion, positions the stock as a blend of income and growth, although the elevated valuation and STELARA-related headwinds remain key risk factors to watch.

Johnson & Johnson stock price and market data

Per recent market data referenced by The Globe and Mail, Johnson & Johnson shares recently closed at USD 270.22 on the New York Stock Exchange, with other sources referencing levels around USD 269.99 as of mid-September 2026.

At a share price close to USD 270 and an annualized dividend of USD 5.36 per share, the implied dividend yield stands near 2 percent, while the analyst consensus target of USD 286.61 leaves the stock trading below that average objective but above the USD 192.92 internal valuation estimate cited by Simplify.